In vitro activity of mersacidin (M87-1551), an investigational peptide antibiotic tested against gram-positive bloodstream isolates.
We measured the in vitro activity of mersacidin (formerly M87-1551) against 183 clinical isolates (vancomycin susceptible) and 12 additional vancomycin-resistant strains of Gram-positive bacteria. The activity for mersacidin increased an average twofold (range, 1.7- to 7.6-fold) in a calcium-enriched medium. The minimum inhibitory concentration (MIC)90 for mersacidin was 8-32 times higher than vancomycin for staphylococci, 4-64 times higher for enterococci, and up to 32 times higher for other organisms tested. The MIC90 for MDL 62873, a comparison compound, was less than or equal to 0.5 micrograms/ml for all species except Staphylococcus haemolyticus (MIC90, 4 micrograms/ml), and it was greater than or equal to 4-fold more active than vancomycin. Against selected vancomycin-resistant strains, mersacidin had MICs greater than or equal to 16 micrograms/ml for enterococci, 4-32 micrograms/ml for Pediococcus, and less than or equal to 2 micrograms/ml for Leuconostoc species. Mersacidin may have some clinical utility in documented infections caused by staphylococci, nonenteric streptococci, Pediococcus, and Leuconostoc.
Barrett
M S
MS
Department of Pathology, University of Iowa College of Medicine, Iowa City.
Wenzel
R P
RP
Jones
R N
RN
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001430:Bacteriocins; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology; D012310:Ristocetin / Q000031:analogs & derivatives; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001430:Bacteriocins; D010455:Peptides; C068029:MDL 62873; C069959:mersacidin; D012310:Ristocetin; D014640:Vancomycin